Alternatives to Triumeq If You Can't Fill Your Prescription

Important: Never stop taking your HIV medication or switch regimens without consulting your doctor first. Changing or interrupting HIV treatment without medical guidance can lead to drug resistance and treatment failure. This guide is intended to help you have an informed conversation with your provider.

Triumeq (abacavir/dolutegravir/lamivudine) is an effective, widely used once-daily HIV regimen. But as a brand-only specialty medication, it can be difficult to find at local pharmacies. If you're facing a delay filling your Triumeq prescription, your doctor may consider switching you temporarily or permanently to an alternative regimen. Here's what they might discuss with you.

Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide)

Biktarvy is the most prescribed HIV regimen in the United States and is widely stocked at both retail and specialty pharmacies. Like Triumeq, it's a once-daily single-tablet regimen built around an integrase strand transfer inhibitor (INSTI) — in Biktarvy's case, bictegravir rather than dolutegravir. It pairs bictegravir with two NRTIs: emtricitabine and tenofovir alafenamide (TAF).

Key differences from Triumeq:

No HLA-B*5701 testing required before starting

Uses TAF (tenofovir alafenamide) instead of abacavir — may be preferred for patients at cardiovascular risk

More widely available at retail pharmacies

Manufactured by Gilead Sciences (not ViiV Healthcare)

Dovato (Dolutegravir/Lamivudine)

Dovato is another single-tablet regimen from ViiV Healthcare. It contains the same dolutegravir found in Triumeq, combined with just one NRTI — lamivudine. It's a two-drug regimen (versus Triumeq's three drugs), which means less medication burden. Clinical trials have shown it to be as effective as three-drug regimens for eligible patients.

Important considerations:

Not appropriate for patients co-infected with hepatitis B (lamivudine alone doesn't adequately treat HBV)

Not recommended if you have prior NRTI resistance mutations

No HLA-B*5701 testing required — no abacavir

Symtuza (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide)

Symtuza is a four-drug single-tablet regimen from Janssen. Instead of an INSTI backbone, it uses darunavir — a protease inhibitor — boosted by cobicistat. Symtuza may be appropriate for patients who have resistance to integrase inhibitors, as it works through a completely different mechanism.

Key considerations:

More drug interactions due to cobicistat (a pharmacokinetic booster)

Must be taken with food for optimal absorption

Different side effect profile than INSTI-based regimens

Cabenuva (Cabotegravir/Rilpivirine)

Cabenuva is a long-acting injectable HIV treatment given as two injections (cabotegravir and rilpivirine) either once monthly or once every two months. For patients who are virologically suppressed and want to stop taking daily pills altogether, Cabenuva offers a completely different experience. It eliminates the pharmacy stocking problem entirely since it's administered in a healthcare setting.

Considerations:

Requires being virologically suppressed (undetectable viral load) before switching

Not appropriate for patients with certain resistance mutations (integrase or rilpivirine)

Requires regular clinic or provider visits for injections

Comparison at a Glance

Biktarvy: 3-drug INSTI, no HLA testing, widely available

Dovato: 2-drug INSTI, same dolutegravir, lighter medication burden

Symtuza: 4-drug PI-based, option if INSTI resistance

Cabenuva: Injectable, no daily pills, monthly or bimonthly dosing

The Most Important Thing to Remember

Before switching medications, exhaust your options for finding Triumeq at another pharmacy. See our guide on why Triumeq is hard to find and how to locate it. A regimen switch involves testing, medical evaluation, and prior authorization — the right first step is usually finding Triumeq at a different pharmacy, not switching medications.

Use medfinder to check which pharmacies near you have Triumeq in stock before pursuing an alternative.